European Journal of Biomedical and Pharmaceutical Sciences

GLYCEMIC EFFECT OF FIXED DOSE COMBINATION OF TENELIGLIPTIN AND METFORMIN IN TYPE-2 DIABETES MELLITUS PATIENTS

Priti Singh, Pooja Agrawal*, Virendra Kushwaha, Ambrish Gupta, Amit Kumar, Saurabh Agarwal and Mahesh Chandra Bindal

ABSTRACT

Background: Teneligliptin is a potent, long acting and highly selective third generation dipeptidyl peptidase-4 (DPP-4) inhibitor recently introduced in India. The main objective of present study was to evaluate the effect of Teneligliptin and Metformin fixed dose combination on glycemic parameters in the treatment of type-2 diabetes mellitus in India. Material and Methods: In this prospective observational study total 70 patients were screened and among them 40 patients were eligible to be enrolled in our study. Teneligliptin (20 mg/day) Metformin (500 mg) fixed dose combination was prescribed in patients with type-2 diabetes and changes in the glycemic parameters were observed at every 4 weeks for 16 weeks treatment which were compared with the baseline. Analysis was done using t-test and a p-value of <0.05 was considered significant. Results: There was statistically significant improvement in mean HbA1c, FBG, and PPBG with teneligliptin and metformin fixed dose therapy. The change in HbA1c level from baseline was −0.79% (7.9 to 7.1%) at 16 weeks of treatment. Percentage of patients achieving target HbA1C (≤7) was 37.5% at 16 weeks. Reduction was also significant (P<0.001) in FBG -32.4mg/dl (149.8-117.4mg/dl) and 2h PPBG 54.3mg/dl (234-179.7mg/dl) at 16 weeks of treatment. There were no cases of hypoglycemia or weight gain reported in the present study. Conclusions: Teneligliptin and Metformin fixed dose combination showed significant improvement in all glycemic parameters and well tolerated at the end of the study period in patients with type-2 diabetes.

Keywords: Teneligliptin, Diabetes Mellitus, DPP-4 inhibitor, HbA1c.